CD24 and neoplasm: In a preclinical model of CD24+ solid tumors, blocking the CD24-Siglec-10 interaction with an anti-CD24 monoclonal antibody (mAb) led to increased TAM-associated phagocytosis in vitro, as well as TAM-dependent tumor growth reduction and enhanced survival in vivo [18].